News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management


01 August 2012 CSL Behring Awards Advocacy Grants to Patient Groups in
Six States: NC, CA, WA, PA, IL, NY

CSL Behring announced today that it has awarded six patient advocacy organizations in the U.S. with Local Empowerment for Advocacy Development (LEAD) grants totaling nearly $70,000. LEAD grants are awarded semiannually and are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or developing a new one.

> Read More
24 July 2012 Jeffrey Modell Foundation Opens Diagnostic Center for
Primary Immunodeficiencies at Midwest Immunology Clinic

The Jeffrey Modell Foundation (JMF), in partnership with CSL Behring, has designated the Midwest Immunology Clinic in Plymouth, Minnesota as a Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies (PI). The Center is headed by Ralph Shapiro, M.D. and is devoted to the diagnosis, treatment and care of people who have PI and autoimmune disorders.

> Read More
02 July 2012 CSL Behring Launches New Hizentra® Dosing Calculator App for Healthcare Professionals on the Move

UK – 2 July, 2012 – CSL Behring UK Ltd today announce the launch of the Hizentra Dosing Calculator App at The British Society for Allergy and Clinical Immunology (BSACI) Annual Scientific Meeting, taking place in Nottingham. The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering its product Hizentra (human normal immunoglobulin, SCIg).

> Read More
27 June 2012 PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rotterdam, Netherlands — 27 June — Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

> Read More
30 May 2012 CSL Behring Submits Marketing Authorization Variation Application to European Medicines Agency (EMA) for Privigen® in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CSL Behring announced today that it has submitted a Variation Application to the European Medicines Agency (EMA) for the use of Privigen® (immune globulin intravenous [human], 10 percent liquid for intravenous administration) in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). CIDP is a rare neurological disorder of the peripheral nerves characterized by symmetrical weakness in the arms and legs that progressively worsens for longer than two months. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia.

> Read More
Page 5 of 11 First | Previous | Next | Last

LinkedIn Twitter Facebook Google+